BioSpace News Archive

Phase 4 study interim analysis showed 61% of patients with persistently active RA reported in the open-label period achieved low disease activity at 12 weeks

Combination of cabozantinib and atezolizumab is well tolerated and shows promising anti-tumor activity

Bristol-Myers Squibb Company today announced the results of a new analysis from the Phase 3 CheckMate -214 study, demonstrating that therapy with Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) was associated with significantly longer treatment-free survival (TFS).

Lannett Company, Inc. today announced that it has entered into an agreement with Adare Pharmaceuticals, Inc., to be the exclusive U.S. distributor of Dexmethylphenidate Hydrochloride Extended Release (ER) Capsules USP (CII), 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg. Lannett expects to commence marketing within a few months.

Mr. Stampacchia was appointed pursuant to the terms of a nomination rights agreement between the Company and Omega Fund Management, LLC.

Tivozanib-Nivolumab Combination Continues to Demonstrate Favorable Efficacy and Safety

Data from experimental models of inflammatory arthritis and multiple sclerosis presented at 2018 ACR/ARHP Annual Meeting and 143rd Annual Meeting of the American Neurological Association

UnitedHealthcare Veteran Jill Winters Appointed CEO to Lead Pathways into Next Phase of Growth

DTC is a subsidiary of the Depository Trust & Clearing Corporation and manages the electronic clearing and settlement of share transactions for publicly-traded companies.

Chardan announced that the firm is acting as lead manager in the follow-on offering for Krystal Biotech, Inc. (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. The underwritten public offering is valued at $60 million of Krystal Biotech’s common stock.